Ayala Pharmaceuticals Inc ADXS

Healthcare Biotechnology

Ayala Pharmaceuticals, Inc. is a clinical-stage oncology company primarily focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations. The Company's lead candidate is aspacytarabine (BST-236), a novel anti-metabolite for first line treatment in unfit acute myeloid leukemia (AML). Aspacytarabine (BST-236) is composed of cytarabine covalently bound to asparagine, acting as a pro-drug of cytarabine. It is also focused on the development and commercialization of proprietary Listeria monocytogenes (Lm)-based antigen delivery products. These efforts are primarily focused on the development of ADXS-504, a Lm-based therapy for early-stage prostate cancer.

GREY:ADXS - Post by User

Ayala Pharmaceuticals Inc

Bullboard Posts

Post by david39on May 07, 2010 9:47am

146 Views

Post# 17073659

ADXS

ADXS was not able to maintain its momentum and the bears were able to drag it down. For the second session, the stock has managed to find good support at
.20 and this could attract some buyers into the market place. Again, the stock has made some impressive gains so I want to wait for this pullback to come to an end before I jump into the market.

Bullboard Posts

Visionstate set to leverage success in the U.S. market